The Commission finally presented, Tuesday, March 11, its proposal for a settlement on critical drugs. Its objective is to reduce the dependencies of the European Union (EU) to countries like China or India and to provide it with a certain sovereignty in a crucial field for citizens.
It is an ancient subject, which took on all its importance at the time of the COVVI-19 crisis, when the Europeans realized that they no longer produced masks or paracetamol and that they depended on the goodwill of distant countries, sometimes autocrats. They were stunned in 2021 to see the American ally block export to the old continent of Astrazeneca vaccines against the virus.
Since then, the pandemic has been defeated, but the shortages of drugs continue to affect the lives of the patients, according to the problems of production of each other. The return to the White House of Donald Trump, who threatens to increase customs duties on European pharmaceutical imports and who is not particularly benevolent towards his historic allies, also worried in Brussels.
You have 73.97% of this article to read. The rest is reserved for subscribers.